These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 861452)

  • 1. Absorbed doses in the marrow during 131I therapy.
    McEwan AC
    Br J Radiol; 1977 May; 50(593):329-31. PubMed ID: 861452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation dose to patients and relatives incident to 131I therapy.
    Zanzonico PB
    Thyroid; 1997 Apr; 7(2):199-204. PubMed ID: 9133684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism.
    Robertson JS; Gorman CA
    J Nucl Med; 1976 Sep; 17(9):826-35. PubMed ID: 956897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of a tracer dose in predicting the kinetics of therapeutic doses of 131I in thyrotoxicosis.
    O'Connor MK; Cullen MJ; Malone JF
    Br J Radiol; 1979 Sep; 52(621):719-26. PubMed ID: 476386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
    Pahlka RB; Sonnad JR
    Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease.
    Nordyke RA; Gilbert FI
    J Nucl Med; 1991 Mar; 32(3):411-6. PubMed ID: 2005449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
    Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of the administered radioiodine doses for the treatment of hyperthyroidism in Belgium.
    Tondeur M; Glinoer D; Sand A; Verelst J; Ham H
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):206-9. PubMed ID: 16886961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of 131I-therapy for hyperthyroidism (author's transl)].
    Tsuchigame T; Yoshii H; Hirota Y; Yasunaga T; Fujimura K; Kaneko T; Katayama K; Ichihara Y; Fukui K; Nakamura I
    Rinsho Hoshasen; 1979 Mar; 24(3):355-60. PubMed ID: 547075
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between severity of thyrotoxicosis and response to 131I therapy.
    Olsen KJ; Nielsen HE; Hansen HH
    Acta Radiol Oncol Radiat Phys Biol; 1978; 17(6):517-23. PubMed ID: 735855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow dosimetry: regional variability of marrow-localizing antibody.
    Sgouros G; Jureidini IM; Scott AM; Graham MC; Larson SM; Scheinberg DA
    J Nucl Med; 1996 Apr; 37(4):695-8. PubMed ID: 8691269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [131I-therapy of hyperthyroidism--10 years' follow-up study].
    Tsuchigame T; Yasunaga T; Hirota Y; Yano K; Ueno S; Bussaka H; Takahashi M; Yoshii H; Fukui K; Nakamura I; Kaneko T
    Rinsho Hoshasen; 1983 May; 28(5):589-93. PubMed ID: 6887615
    [No Abstract]   [Full Text] [Related]  

  • 16. [Follow-up of 131I-therapy of hyperthyroidism (author's transl)].
    Kinoshita F; Maekawa A; Kohda E; Kokamoto J; Shichiri Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 1976; 36(2):128-42. PubMed ID: 1064000
    [No Abstract]   [Full Text] [Related]  

  • 17. [131I therapy in hyperthyroidism. Results of treatment from 1960-1974].
    Heinze HG; Schenk F
    Nuklearmedizin; 1977 Feb; 16(1):1-12. PubMed ID: 846862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dosimetry of the hematopoietic system in radioiodine therapy of thyroid cancer].
    Günter HH; Junker D; Schober O; Hundeshagen H
    Strahlenther Onkol; 1987 Mar; 163(3):185-91. PubMed ID: 3563879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Whole body counting of 131I administered patients with hyperthyroidism, and estimations of absorbed doses of 131I to various organs (author's transl)].
    Saegusa K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1974 Jun; 34(6):404-15. PubMed ID: 4216878
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of hyperthyroidism using 131I: a retrospective study].
    Kamphuis JJ
    Ned Tijdschr Geneeskd; 1980 Jun; 124(26):1045-9. PubMed ID: 7402371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.